Learn more about the efficacy and effects of serpotinib/serpatinib

Selpercatinib is a RET receptor tyrosine kinase inhibitor indicated for the treatment of RET-driven non-small cell lung cancer, medullary thyroid cancer and thyroid cancer in appropriate patient populations. Seputinib exerts anti-tumor activity in certain cancers by inhibiting mutated forms of RET tyrosine kinase. Because Seputinib is more specific for RET than other tyrosine kinases, it is considered to have a better safety profile than other multikinase inhibitors.

In the lung cancer trialLIBRETTO-431, treating patients with advanced non-small cell lung cancer (NSCLC) containing a RET fusion with seputinib more than doubled median progression-free survival compared with patients who received pembrolizumab with or without chemotherapy. In the medullary thyroid cancer trial LIBRETTO-531, seputinib outperformed two other targeted therapies based on several measures, including progression-free survival in patients with RET-mutated advanced medullary thyroid cancer.

Up to now, the original research drug is sold in China under the name of Seputinib, but it is not included in medical insurance. The price of each box of 80mg*56 tablets may be more than 10,000 yuan. There are European and American versions of the original drugs sold overseas, with the price of each box ranging from 20,000 to more than 100,000 yuan (prices may fluctuate due to exchange rates). Generic drugs of Seputinib have also been put on the market for sale overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 40mg*120 capsules produced by a Laos pharmaceutical factory is more than RMB 4,000 per box (the price may fluctuate due to exchange rates).